US2018338991A1PendingUtilityA1

Nad biosynthesis and precursors for the treatment and prevention of cancer and proliferation

53
Assignee: HARVARD COLLEGEPriority: Oct 9, 2012Filed: Dec 7, 2017Published: Nov 29, 2018
Est. expiryOct 9, 2032(~6.2 yrs left)· nominal 20-yr term from priority
Inventors:David A. SinclairAna P. GomesLindsay Edward Wu
A01K 2217/075A61K 31/7064A01K 2227/105C12Y 204/02012A61K 48/005C12Y 207/07001A01K 2267/035A61K 31/706A61P 35/00A61K 38/45
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed herein are novel compositions and methods for the treatment of age-related diseases, mitochondrial diseases, the improvement of stress resistance, the improvement of resistance to hypoxia and the extension of life span. Also described herein are methods for the identification of agents useful in the foregoing methods. Methods and compositions are provided for the treatment of diseases or disorders associated with mitochondrial dysfunction. The invention relates to methods for treatment and prevention of cancer by administering agents that increase levels of NAD+, such as NAD+ precursors or agents involved in NAD+ biosynthesis.

Claims

exact text as granted — not AI-modified
1 .- 7 . (canceled) 
     
     
         8 . A method for modulating cell proliferation in a subject in need thereof, comprising
 administering to the subject an amount of nicotinamide mononucleotide (NMN), or a salt thereof, or a prodrug thereof, effective to increase the level of nicotinamide adenine dinucleotide (NAD+) in the subject.   
     
     
         9 . (canceled) 
     
     
         10 . The method of  claim 8 , wherein the NMN or salt thereof, or prodrug thereof, is administered orally. 
     
     
         11 . The method of  claim 8 , wherein the NMN, or salt thereof, or prodrug thereof, is administered at a dose of between 0.5-5 grams per day. 
     
     
         12 .- 13 . (canceled) 
     
     
         14 . The method of  claim 8 , wherein the subject is a human. 
     
     
         15 . The method of  claim 8 , wherein the NMN or salt thereof, or prodrug thereof, is administered as a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the NMN or salt thereof, or prodrug thereof. 
     
     
         16 . The method of  claim 15 , wherein the pharmaceutical composition is adapted for oral administration. 
     
     
         17 . The method of  claim 15 , wherein the NMN or salt thereof, or prodrug thereof, is administered orally. 
     
     
         18 . The method of  claim 15 , wherein the subject is a human. 
     
     
         19 . The method of  claim 11 , wherein the NMN or salt thereof, or prodrug thereof, is administered orally. 
     
     
         20 . The method of  claim 11 , wherein the subject is a human. 
     
     
         21 . The method of  claim 11 , wherein the NMN or salt thereof, or prodrug thereof, is administered as a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the NMN or salt thereof, or prodrug thereof. 
     
     
         22 . The method of  claim 21 , wherein the pharmaceutical composition is adapted for oral administration. 
     
     
         23 . The method of  claim 21 , wherein the NMN or salt thereof, or prodrug thereof, is administered orally. 
     
     
         24 . A method for modulating cell proliferation in a subject in need thereof, comprising administering to the subject an amount of nicotinamide mononucleotide (NMN), or a salt thereof, effective to increase the level of nicotinamide adenine dinucleotide (NAD+) in the subject. 
     
     
         25 . The method of  claim 24 , wherein the NMN or salt thereof is administered orally. 
     
     
         26 . The method of  claim 24 , wherein the subject is a human. 
     
     
         27 . The method of  claim 24 , wherein the NMN or salt thereof is administered as a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the NMN or salt thereof. 
     
     
         28 . The method of  claim 27 , wherein the pharmaceutical composition is adapted for oral administration. 
     
     
         29 . The method of  claim 27 , wherein the NMN or salt thereof is administered orally. 
     
     
         30 . The method of  claim 27 , wherein the subject is a human. 
     
     
         31 . The method of  claim 24 , wherein the NMN or salt thereof is administered at a dose of between 0.5-5 grams per day. 
     
     
         32 . The method of  claim 31 , wherein the NMN or salt thereof is administered orally. 
     
     
         33 . The method of  claim 31 , wherein the subject is a human. 
     
     
         34 . The method of  claim 31 , wherein the NMN or salt thereof is administered as a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the NMN or salt thereof. 
     
     
         35 . The method of  claim 34 , wherein the pharmaceutical composition is adapted for oral administration. 
     
     
         36 . The method of  claim 34 , wherein the NMN or salt thereof is administered orally.

Join the waitlist — get patent alerts

Track US2018338991A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.